Concerns About Addiction: Bringing Clarity to Confusion about Addiction Terminology Aaron M. Gilson, MS, MSSW, PhD Research Program Manager/Senior Scientist.

Slides:



Advertisements
Similar presentations
Abuse or Dependence? Assessing the Alcoholic patient in the Clinic. Antoni Gual Alcohol Unit Psychiatry Department Neurosciences Institute.
Advertisements

Substance Related Disorders
Welcome to the Open Sky Webinar! We will start at 6pm- see you soon.
Opioid Update F ederation of S tate M edical B oards Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain July 2013 F ederation.
DSM – 5 Substance-Related and Addictive Disorders
The purpose is not to imply everyone on controlled substances will become addicted!!! Everyone on controlled substances is, however, at increased risk.
Pain and Chemical Dependency Not an “Either – Or” proposition Douglas Gourlay, MD, FRCPC, FASAM Wasser Pain Centre, Toronto ON.
PSK Annual Conference 2008 Palliative care medicine: A balanced approach to opioid availability and safe use in Kenya Presenter: Dr. Bilha Kiama-Murage.
What’s New in DSM-5 For Clinicians Working with Mandated Populations State Specialty Court Conference DuAne L. Young The Change Companies®
Facts In 2008, an estimated 20.1 million Americans aged 12 or older were current (past-month) illicit drug users. (8.0% of the population) million.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December 2007.
Why Not Use the DSM-IVR for Diagnosing Addiction? Reason #147: Inadequacies of using qualitative indices for a quantitative problem.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2011.
Practice Principles and Pharmacology CSD 5970 Counseling the Chemically Dependent.
Substance Abuse Screening and Assessment CSD 5970.
1 Prescription Drug Nonmedical Use and Abuse in Older Women Drug abuse in the 21 st century: what lies ahead for the baby boomers? Linda Simoni-Wastila,
Alcohol Medical Scholars ALCOHOLISM AND POSTTRAUMATIC STRESS DISORDER Joe E. Thornton, M.D.
SBIRT Module 2: Screening for Substance Use Problems in Primary Care UCSF SBIRT Collaborative Education Project Janice Tsoh, PhD.
Medical Model of Addiction
How To Do… Screening. Screening: Why do SBIRT? “Who are the addicts?”
Chapter 4 Screening and Assessment of Alcohol/Drug Problems.
©2010 McGraw-Hill Higher Education. All rights reserved. Chapter 4 Definitions of Substance Abuse, Dependence, and Addiction.
Aberrant Drug-taking Behaviors in Medically Ill Pain Patients Aberrant Drug-taking Behaviors in Medically Ill Pain Patients Steven D. Passik, PhD Director,
Drug Diversion, Sources, and Extent: United States Case Study Aaron M. Gilson, MS, MSSW, PhD Research Program Manager/Senior Scientist Pain & Policy Studies.
North Carolina TASC Clinical Series Training Module Eight: DSM -IV.
DOUGHNUTSDOUGHNUTS. Opioid Agonist Therapy The Skinny on Methadone et al.
Assessment of Substance Use Disorders
Copyright © 2007 by The McGraw-Hill Companies, Inc. All rights reserved. Chapter 17 Substance-Related Disorders – Focus on Alcoholism.
Characteristics of Patients Using Extreme Opioid Dosages in the Treatment of Chronic Low Back Pain In this sample of 204 participants, 70% were female,
Copyright (c) Pearson Education 2010 Drugs, Behavior, and Modern Society SIXTH EDITION Charles F. Levinthal Chapter 2 Drug-taking Behavior: The Personal.
ON THE MOVE Department of Corrections GEORGIA Presented by: Rachael G. Hopkins, LPC, CPCS, CCAADC, CCDP-D, CCS Substance Abuse Unit Risk Reduction Services.
Chapter 2 Drug-taking Behavior: The Personal and Social Concerns.
Opioid Use: What are the technological, clinical, ethical, and regulatory issues? Michael Von Korff Group Health Research Institute.
DSM-5 ™ in Action: Diagnostic and Treatment Implications Section 2, Chapters 5–13 PART 2 of Section 2 Chapters 8–16 by Sophia F. Dziegielewski, PhD, LCSW.
Opioid Use in Workers’ Compensation Suzanne Novak, MD, PhD November 2008.
Terms & Definitions Samhsa’s Co-Occurring Center for Excellence COCE.
Defining substance abuse Health Psychology. Introduction to Substances.
Methods to Evaluate and Improve National Policy: Focus on 2011 WHO Guidelines and PPSG Global Policy Evaluation Aaron M. Gilson, MS, MSSW, PhD Research.
Single Convention on Narcotic Drugs Establishes a regulatory system for narcotic drugs government authorization is required for participation in the trade.
Oliva Rosella Euro Weight Loss-2015 Frankfurt, Germany August 18 – 20, 2015.
Ensuring Availability and Preventing Diversion International Pain Policy Fellowship August 7, 2012 David E. Joranson University of Wisconsin Pain & Policy.
Introduction to Healthcare and Public Health in the US The Evolution and Reform of Healthcare in the US Lecture b This material (Comp1_Unit9b) was developed.
Addiction and dependence Disclaimer: This presentation contains information on the general principles of pain management. This presentation cannot account.
M. Fe Caces, Ph.D. Office of National Drug Control Policy Executive Office of the President September 2004 Gender Differences in Drug Treatment Data in.
Substance abuse. Definition It’s a mental disorder that shows symptoms and maladaptive behavioral changes with the use of substances that affect the CNS.
Preventing drug diversion: Principles and concepts International Pain Policy Fellowship August 7, 2012 David E. Joranson Distinguished Scientist, Founder.
Pain Management: Narcotics, Implantable Therapies Maher Fattouh MD Adjunct Assistant Clinical Professor University Wisconsin Medical Director, Advanced.
دکترارتین کمالی ثابتی ( متخصص پزشکی قانونی ومسمومیتها )
Chronic Pain Management Harald Lausen, DO, MA FCM Clerkship SIU School of Medicine.
Current Concepts in Pain Management
Legal and Regulatory Issues in Pain Management
Medi-cal covered inpt tx in SoCo?
Evidence-based Medicine
2. Drug Misuse and Dependency
Case Presentations.
COMMONLY USED TERMS DR. JOSEPH B. FAMA FPSMS CLINICAL DEPARTMENT HEAD DOH-DRUG TREATMENT AND REHABILITATION CENTER.
Drug Use as a Social Problem
DSM-IV-TR, APA, 2000 Criteria for Substance Dependence:
Substance Use Disorders
Assessing Opioid Use Disorder, part 1
Diagnosis and Recognition of OUD
Off-label use means all uses of a marketed drug not detailed in the summary of the product characteristics including therapeutic indication, use in age-
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Office of Aerospace. Medicine
Risk Management During Opioid Analgesic Prescribing for Chronic Pain
Gender Issues and Addiction
Substance Abuse.
Bassett-UMass MAT ECHO.
Opiate misuse among our seniors
Acute Pain Management & Addiction
Presentation transcript:

Concerns About Addiction: Bringing Clarity to Confusion about Addiction Terminology Aaron M. Gilson, MS, MSSW, PhD Research Program Manager/Senior Scientist Pain & Policy Studies Group International Pain Policy Fellowship Pain & Policy Studies Group WHO Collaborating Center for Pain Policy & Palliative Care University of Wisconsin Carbone Cancer Center August 6, 2012

Evolution of WHO Terminology and Beliefs  World Health Organization Expert Committees  1950 “Drug Addiction”*  1957 “Drug Addiction”  1964 “Drug Dependence”  1969 “Drug Dependence”  1990 “Drug Dependence”  1993 “Drug Dependence”*  1998 “Dependence Syndrome”*  International Classification of Diseases

 Three elements co-occur within the preceding year: 1)Strong desire 2)Difficulties in control 3)Use occurs despite harm 4)Neglect of pleasures; increased time to obtain substance 5)Tolerance 6)Physical withdrawal * The diagnostic requirement of essential characteristics would exclude patients who are being treated with opioids for the relief of pain. “Dependence Syndrome” ~ Current International Diagnosis ~ World Health Organization. International Classification of Diseases (10 th edition). 1992;75-76.

 Maladaptive pattern of substance use, leading to clinically significant impairment or distress  Manifested by three (or more) of the following:  Tolerance  Withdrawal  Use in larger amounts or durations than intended  Use persists despite desire or efforts to control  Much time spent to obtain, use, or recover from effects  Decreased social, occupational, or recreational activities  Use occurs despite harm American Psychiatric Association. Diagnostic and Statistical Manual (4 th edition). 1994;181. “Substance Dependence” ~ Current U.S. Diagnosis ~

 Maladaptive pattern of substance use, leading to clinically significant impairment or distress  Manifested by one (or more) of the following:  Failure to fulfill major role obligations at work, school, or home  Recurrent use in situations in which it is physically hazardous  Recurrent legal problems  Persistent or recurrent social or interpersonal problems American Psychiatric Association. Diagnostic and Statistical Manual (4 th edition). 1994; “Substance Abuse” ~ Current U.S. Diagnosis ~

 Maladaptive pattern of substance use leading to clinically significant impairment or distress  Manifested by two (or more) of the following:  Failure to fulfill major role obligations at work, school, or home  Recurrent use in situations in which it is physically hazardous  Persistent or recurrent social or interpersonal problems  Use in larger amounts or durations than intended  Use persists despite desire or efforts to control  Much time spent to obtain, use, or recover from effects  Decreased social, occupational, or recreational activities  Continues despite knowledge of having a problem  Craving or strong desire to use American Psychiatric Association. DSM-5 Substance-Related Disorders Work Group. “Substance Use Disorder” ~ Future U.S. Diagnosis ~

Additional indicators  Tolerance  Withdrawal syndrome Note: Tolerance or Withdrawal are not counted for those taking medications under medical supervision such as analgesics, antidepressants, anti-anxiety medications, or beta-blockers American Psychiatric Association. DSM-5 Substance-Related Disorders Work Group. “Substance Use Disorder” ~ Future U.S. Diagnosis ~

Calls for Policy Reform  UN International Narcotics Control Board  U.S. Institute of Medicine  Council of Europe  UN Economic and Social Council  World Health Organization

International Narcotics Control Board 1989, 1996, 2005, 2007, 2010  Governments should examine their drug control policies for the presence of overly restrictive provisions that may impact their health care system in the delivery of pain relief, and take corrective action as needed  Addiction and its terminology International Narcotics Control Board. Reports for 1989, 1995, 2004, 2007, and New York, NY: United Nations; 1989, 1996, 2005, 2007, 2010.

World Health Organization. Achieving Balance in National Opioids Control Policy: Guidelines for Assessment. Geneva, Switzerland: WHO; WHO Ensuring Balance Guideline, 2011  Guideline 10: Terminology in national drug control legislation and policies should be clear and unambiguous in order not to confuse the use of controlled medicines for medical and scientific purposes with misuse  “dependence” vs. “dependence syndrome”  avoid use of stigmatizing terms like “addiction” in legislation

Occurrence of Addiction in Medical Treatment with Rx Opioids Webster L, Webster R. Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the opioid risk tool. Pain Medicine. 2005;6: Theoretical Prevalence Theoretical Prevalence Total Pain Population Aberrant Behaviors 40% Abuse 20% Addiction 2-5%

Occurrence of Addiction in Medical Treatment with Rx Opioids  Fleming et al.3.1%  UW outpatients with chronic non-cancer pain  DSM “substance dependence”  Fishbain et al.3.3%  Meta-analysis of studies of patients with chronic non-cancer pain  addiction (typically undefined) Statistical Prevalence Statistical Prevalence Fishbain et al. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Medicine. 2008;9: Fleming et al. Substance use disorders in a primary care sample receiving daily opioid therapy. Journal of Pain. 2007;8:

Occurrence of Addiction in Medical Treatment with Rx Opioids Boscarino et al. Risk factors for drug dependence among out-patients on opioid therapy in a large US health- care system. Addiction. 2010;105: < 65 years 3.59 < 65 years + Pain impairment 4.63 < 65 years + Pain impairment + Depression Hx < 65 years + Pain impairment + Depression Hx + Psychotropic meds < 65 years + Pain impairment + Depression Hx + Psychotropic meds + Severe Rx opioid dpnd Hx < 65 years + Pain impairment + Depression Hx + Psychotropic meds + Severe Rx opioid dpnd Hx + Rx opioid abuse Hx Current Rx opioid dependence (DSM-IV) (n=705; 25.8%) Odds Ratio

Need to Consider the Spectrum of Non-Medical Use of Rx Opioids Misuse (unintentional) e.g., - sharing with others - unknowingly taking larger amounts than directed - inadvertent poisoning Dependence Syndrome (“Addiction”) Abuse Misuse (intentional) e.g., - recreational use for psychic effects - decide to increase dose for pain control - suicidal gesture or attempt Use involving aberrant behaviors e.g., - forging/altering prescriptions - going to multiple doctors - stealing drugs Concurrent use of illicit drugs or undisclosed Rx medication use

Conclusions  Evolution in concept and terminology  New medical and scientific understanding  Research evidence about prevalence  Fear of addiction limits access to pain relief  Influences content of laws and other policies  Definitions in laws of many countries have not changed  Ample expert guidance and tools exists  To evaluate national drug control and healthcare policies  To correct the definitions  Changes have legal and clinical implications

Action Steps: Communicating to Others  Do not assume that the other person understands what is meant by the term “addiction”  find out about his or her beliefs and offer to clarify if necessary  Clarify how available terminology relates to currently- accepted standards (WHO concept of “dependence syndrome”)  Ensure that “addiction” does not characterize only the development of withdrawal syndrome or tolerance  Clarify that “addiction” cannot always be identified by behaviors alone  motivations for such behaviors are important

 Clarify that available U.S. research suggests that iatrogenic addiction is more prevalent when patients have existing co-morbidities (e.g., substance abuse history)  practitioners need to assess for co-morbidities, and then monitor for the development of addiction throughout treatment  Determine if data are available in your country to document the prevalence or incidence of “addiction”  Determine the sources of opioid analgesics used by people with the disease of addiction  Determine how perceptions about addiction are influencing the treatment of people with chronic pain Action Steps: Communicating to Others